Different oral cancer scenarios to personalize targeted therapy: Boron Neutron Capture Therapy translational studies

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Rivera C. Essentials of oral cancer. Int. J. Clin. Exp. Pathol. 8(9), 11884–11894 (2015).
  Medline CASGoogle Scholar
• 2. Islam S, Abiko Y, Uehara O, Chiba I. Sirtuin 1 and oral cancer. Oncol. Lett. 17(1), 729–738 (2019).
  Medline CASGoogle Scholar
• 3. Kumar M, Nanavati R, Modi TG, Dobariya C. Oral cancer: etiology and risk factors: a review. J. Cancer. Res. Ther. 12(2), 458–463 (2016).
  Medline CASGoogle Scholar
• 4. Andreassen CN, Eriksen JG, Jensen K et al. IMRT – biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer. Oral Oncol. 86, 91–99 (2018).
  Medline CASGoogle Scholar
• 5. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res. 63(8), 1727–1730 (2003).
  Medline CASGoogle Scholar
• 6. Jaiswal G, Jaiswal S, Kumar R, Sharma A. Field cancerization: concept and clinical implications in head and neck squamous cell carcinoma. J. Exp. Ther. Oncol. 10, 209–214 (2013).
  MedlineGoogle Scholar
• 7. Monti-Hughes A, Aromando RF, Pérez MA, Schwint AE, Itoiz ME. The hamster cheek pouch model for field cancerization studies. Periodontol. 2000 67(1), 292–311 (2015a). • This review by our group describes the hamster cheek pouch oral cancer model and its value to study the inhibitory effect of BNCT on the development of new tumors and associated mucositis in the precancer model (6-week cancerization protocol).
  MedlineGoogle Scholar
• 8. Li CC, Shen Z, Bavarian R, Yang F, Bhattacharya A. Oral cancer: genetics and the role of precision medicine. Dent. Clin. North. Am. 62(1), 29–46 (2018). •• This paper provides current general concepts about oral cancer and highlights the importance of the integration of science and medicine for the study of new targeted and personalized strategies in oral cancer.
  MedlineGoogle Scholar
• 9. Ford PJ, Farah CS. Early detection and diagnosis of oral cancer: strategies for improvement. J. Cancer Policy 1, e2–e7 (2013).
  Google Scholar
• 10. Chung CM, Lee CH, Chen MK et al. Combined genetic biomarkers and betel quid chewing for identifying high-risk group for oral cancer occurrence. Cancer Prev. Res. (Phila) 10(6), 355–362 (2017).
  Medline CASGoogle Scholar
• 11. Rimal J, Shrestha A, Maharjan IK, Shrestha S, Shah P. Risk assessment of smokeless tobacco among oral precancer and cancer patients in eastern developmental region of Nepal. Asian Pac. J. Cancer Prev. 20(2), 411–415 (2019).
  MedlineGoogle Scholar
• 12. Jensen SB, Peterson DE. Oral mucosal injury caused by cancer therapies: current management and new frontiers in research. J. Oral Pathol. Med. 43(2), 81–90 (2014).
  MedlineGoogle Scholar
• 13. Cinausero M, Aprile G, Ermacora P et al. New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front. Pharmacol. 8, 354 (2017). •• Paper that summarizes the current epidemiology of mucositis, the pathobiology, risk factors and mentions animal models as useful tools to study this adverse effect.
  MedlineGoogle Scholar
• 14. Aghamohammadi A, Moslemi D, Akbari J et al. The effectiveness of Zataria extract mouthwash for the management of radiation-induced oral mucositis in patients: a randomized placebo-controlled double-blind study. Clin. Oral Investig. 22(6), 2263–2272 (2018).
  MedlineGoogle Scholar
• 15. Mallick S, Benson R, Rath GK. Radiation induced oral mucositis: a review of current literature on prevention and management. Eur. Arch. Otorhinolaryngol. 273(9), 2285–2293 (2016).
  MedlineGoogle Scholar
• 16. Sangild PT, Shen RL, Pontoppidan P, Rathe M. Animal models of chemotherapy-induced mucositis: translational relevance and challenges. Am. J. Physiol. Gastrointest. Liver Physiol. 314(2), G231–G246 (2018).
  Medline CASGoogle Scholar
• 17. Villa A, Sonis ST. Mucositis: pathobiology and management. Curr. Opin. Oncol. 27(3), 159–64 (2015).
  Medline CASGoogle Scholar
• 18. Kankaanranta L, Seppälä T, Koivunoro H et al. Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a Phase I/II trial. Int. J. Radiat. Oncol. Biol. Phys. 82(1), e67–e75 (2012). • This paper is important as an example of a clinical study of BNCT for head and neck cancer patients.
  MedlineGoogle Scholar
• 19. Lim D, Quah DS, Leech M, Marignol L. Clinical potential of boron neutron capture therapy for locally recurrent inoperable previously irradiated head and neck cancer. Appl. Radiat. Isot. 106, 237–241 (2015).
  Medline CASGoogle Scholar
• 20. Schwint AE, Trivillin VA. ‘Close-to-ideal’ tumor boron targeting for boron neutron capture therapy is possible with ‘less-than-ideal’ boron carriers approved for use in humans. Ther. Deliv. 6(3), 269–272 (2015).
  CASGoogle Scholar
• 21. Barth RF, Zhang Z, Liu T. A realistic appraisal of boron neutron capture therapy as a cancer treatment modality. Cancer Commun. 38(1), 36 (2018).
  Google Scholar
• 22. Farhood B, Samadian H, Ghorbani M, Zakariaee SS, Knaup C. Physical, dosimetric and clinical aspects and delivery systems in neutron capture therapy. Rep. Pract. Oncol. Radiother. 23(5), 462–473 (2018).
  MedlineGoogle Scholar
• 23. Trivillin VA, Heber EM, Nigg DW et al. Therapeutic success of boron neutron capture therapy (BNCT) mediated by a chemically nonselective boron agent in an experimental model of oral cancer: a new paradigm in BNCT radiobiology. Radiat. Res. 166(2), 387–396 (2006).
  Medline CASGoogle Scholar
• 24. Monti Hughes A, Pozzi EC, Thorp S et al. Boron neutron capture therapy for oral precancer: proof of principle in an experimental animal model. Oral Dis. 19(8), 789–795 (2013).
  MedlineGoogle Scholar
• 25. Menéndez PR, Roth BM, Pereira MD et al. BNCT for skin melanoma in extremities: updated Argentine clinical results. Appl. Radiat. Isot. 67(7-8 Suppl), S50–53 (2009).
  Medline CASGoogle Scholar
• 26. Hiratsuka J, Kamitani N, Tanaka R et al. Boron neutron capture therapy for vulvar melanoma and genital extramammary Paget’s disease with curative responses. Cancer Commun. 38(1), 38 (2018).
  Google Scholar
• 27. Wang LW, Liu YH, Chou FI, Jiang SH. Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing-Hua Open Pool Reactor. Cancer Commun. 38(1), 37 (2018).
  Google Scholar
• 28. Kikuchi S, Kanoh D, Sato S, Sakurai Y, Suzuki M, Nakamura H. Maleimide-functionalized closo-dodecaborate albumin conjugates (MID-AC): Unique ligation at cysteine and lysine residues enables efficient boron delivery to tumor for neutron capture therapy. J. Control. Rel. 237, 160–167 (2016).
  Medline CASGoogle Scholar
• 29. Fuentes I, García-Mendiola T, Sato S et al. Metallacarboranes on the road to anticancer therapies: cellular uptake, DNA interaction, and biological evaluation of cobaltabisdicarbollide [COSAN]. Chemistry 24(65), 17239–17254 (2018).
  Medline CASGoogle Scholar
• 30. Teixidor F, Sillanpää R, Pepiol A, Lupu M, Viñas C. Synthesis of globular precursors. Chemistry 1 21(36), 12778–12786 (2015).
  Medline CASGoogle Scholar
• 31. Barth RF, Mi P, Yang W. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun. 838, 35 (2018).
  Google Scholar
• 32. Barth RF. From the laboratory to the clinic: How translational studies in animals have lead to clinical advances in boron neutron capture therapy. Appl. Radiat. Isot. 106, 22–28 (2015).
  Medline CASGoogle Scholar
• 33. Workman P, Aboagye EO, Balkwill F et al. Committee of the National Cancer Research Institute (2010) Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer. 102(11), 1555–1577 (2010).
  Medline CASGoogle Scholar
• 34. Sonis ST, Peterson RL, Edwards LJ et al. Defining mechanisms of action of interleukin-11 on the progression of radiation induced oral mucositis in hamsters. Oral Oncol. 36, 373–381 (2000).
  Medline CASGoogle Scholar
• 35. López Castaño F, Oñate-Sánchez RE, Roldán-Chicano R, Cabrerizo-Merino MC. Measurement of secondary mucositis to oncohematologic treatment by means of different scale. Med. Oral Patol. Oral Cir. Bucal 10, 412–421 (2005).
  MedlineGoogle Scholar
• 36. Patil S, Rao R, Raj T. Animal models – decoding the molecular biology of oral cancer. J. Contemp. Dent. Pract. 16(4), i–ii (2015).
  Google Scholar
• 37. El-Bayoumy K, Chen KM, Zhang SM et al. Carcinogenesis of the oral cavity: environmental causes and potential prevention by black raspberry. Chem. Res. Toxicol. 30(1), 126–144 (2017).
  Medline CASGoogle Scholar
• 38. Nagini S, Kowshik J. The hamster buccal pouch model of oral carcinogenesis. Methods Mol. Biol. 1422, 341–350 (2016).
  Medline CASGoogle Scholar
• 39. Kreimann EL, Itoiz ME, Longhino J, Blaumann H, Calzetta O, Schwint AE. Boron neutron capture therapy for the treatment of oral cancer in the hamster cheek pouch model. Cancer Res. 61, 8638–8642 (2001). •• This paper by our group was the first report of the efficacy of BNCT for the treatment of head and neck tumors in an experimental model. It preceded the first clinical trial of BNCT for head and neck cancer.
  Medline CASGoogle Scholar
• 40. Kato I, Ono K, Sakurai Y et al. Effectiveness of BNCT for recurrent head and neck malignancies. Appl. Radiat. Isot. 61(5), 1069–1073 (2004).
  Medline CASGoogle Scholar
• 41. Heber EM, Hawthorne MF, Kueffer PJ et al. Therapeutic efficacy of boron neutron capture therapy mediated by boron-rich liposomes for oral cancer in the hamster cheek pouch model. Proc. Natl Acad. Sci. USA 111(45), 16077–16081 (2014).
  Medline CASGoogle Scholar
• 42. Heber EM, Monti Hughes A, Pozzi EC et al. Development of a model of tissue with potentially malignant disorders (PMD) in the hamster cheek pouch to explore the long-term potential therapeutic and/or toxic effects of different therapeutic modalities. Arch. Oral Biol. 55(1), 46–51 (2010). • This paper by our group compares different oral carcinogenesis protocols in terms of tumor development and follow-up of the animals after cancerization.
  Medline CASGoogle Scholar
• 43. Monti Hughes A, Pozzi EC, Heber EM et al. Boron Neutron Capture Therapy (BNCT) in an oral precancer model: therapeutic benefits and potential toxicity of a double application of BNCT with a six-week interval. Oral Oncol. 47, 1017–1022 (2011).
  MedlineGoogle Scholar
• 44. González SJ, Pozzi ECC, Monti Hughes A et al. Photon iso-effective dose for cancer treatment with mixed field radiation based on dose-response assessment from human and an animal model: clinical application to boron neutron capture therapy for head and neck cancer. Phys. Med. Biol. 62(20), 7938–7958 (2017).
  Medline CASGoogle Scholar
• 45. Monti Hughes A, Pozzi E, Thorp SI et al. Histamine reduces boron neutron capture therapy-induced mucositis in an oral precancer model. Oral Dis. 21(6), 770–777 (2015b).
  MedlineGoogle Scholar
• 46. Medina VA, Rivera ES. Histamine receptors and cancer pharmacology. Br. J. Pharmacol. 161(4), 755–767 (2010).
  Medline CASGoogle Scholar
• 47. Monti Hughes A, Longhino J, Boggio E et al. Boron neutron capture therapy (BNCT) translational studies in the hamster cheek pouch model of oral cancer at the new “B2” configuration of the RA-6 nuclear reactor. Radiat. Environ. Biophys. 56(4), 377–387 (2017).
  MedlineGoogle Scholar
• 48. Detta A, Cruickshank GS. L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res. 69(5), 2126–2132 (2009).
  Medline CASGoogle Scholar
• 49. Yoshimoto M, Kurihara H, Honda N et al. Predominant contribution of L-type amino acid transporter to 4-borono-2-(18)F-fluoro-phenylalanine uptake in human glioblastoma cells. Nucl. Med. Biol. 40(5), 625–629 (2013).
  Medline CASGoogle Scholar
• 50. Baskar R, Dai J, Wenlong N, Yeo R, Yeoh KW. Biological response of cancer cells to radiation treatment. Front. Mol. Biosci. 1(24), 1–9 (2014).
  Medline CASGoogle Scholar
• 51. Tani H, Kurihara H, Hiroi K et al. Correlation of (18)F-BPA and (18)F-FDG uptake in head and neck cancers. Radiother. Oncol. 113(2), 193–197 (2014).
  MedlineGoogle Scholar
• 52. Kobayashi K, Kurihara H, Watanabe Y et al. In vivo spatial correlation between (18)F-BPA and (18)F-FDG uptakes in head and neck cancer. Appl. Radiat. Isot. 115, 138–146 (2016).
  Medline CASGoogle Scholar